Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

NLRP6 regulates ZAP-70-erk signaling in both murine and human T cells and influences acute graft-versus-host disease(GVHD)

Blood (2025) 146 (Supplement 1): 4090.

https://doi.org/10.1182/blood-2025-4090

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Blood (2025) 146 (Supplement 1): 998.

https://doi.org/10.1182/blood-2025-998

Published: 2025

Journal Articles

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Mark Levis, Alexander Perl, Jianda Hu, Heeje Kim, Vladimir Ivanov, Hisayuki Yokoyama, Naoko Hosono, Er-Lie Jiang, Dong-Yeop Shin, Bartlomiej Getta, Ashish Bajel, Jamie Jung-Hee An, Dina Elsouda, Juan Ariza, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 42.

https://doi.org/10.1182/blood-2025-42

Published: 2025

Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Blood (2024) 144 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2024-209232

Published: 2024

Journal Articles

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Alexander E. Perl, Mark J. Levis, Andrew Wei, Hee-je Kim, June-won Cheong, Yu Zhang, Jian Li, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Jamie Jung-Hee An, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2024-204831

Published: 2024

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Hematopoietic Stem/Progenitor Cell Intrinsic SAM Synthesis Is Required to Prevent p53 Pathway Activation By Maintaining DNA Stability

Eijiro Furukawa, Hiroki Kato, Sayaka Sano, Yan Yan, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Daisuke Saigusa, Tohru Fujiwara, Kazuhiko Igarashi, Hideo Harigae

Blood (2023) 142 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2023-180384

Published: 2023

Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Blood (2023) 142 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2023-178798

Published: 2023

Journal Articles

Roles for Heme Synthesis in the Maintenance of Hematopoietic Stem and Progenitor Cells

Yan Yan, Hiroki Kato, Sayaka Sano, Eijiro Furukawa, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Tohru Fujiwara, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

Blood (2023) 142 (Supplement 1): 2682.

https://doi.org/10.1182/blood-2023-174202

Published: 2023

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

Transcription Factor GATA2 Is Inevitable for the Survival and Proper Differentiation of Thymic Multipotent Progenitor Cells By Gene Expression Orchestration

Sayaka Sano, Hiroki Kato, Yan Yan, Eijiro Furukawa, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Tohru Fujiwara, Hideo Harigae

Blood (2023) 142 (Supplement 1): 1182.

https://doi.org/10.1182/blood-2023-178454

Published: 2023

Journal Articles

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

Hisayuki Yokoyama, Koji Ando, Noriko Fukuhara, Hiroatsu Iida, Suguru Fukuhara, Hiroshi Miyake, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Akio Mizutani, Daisuke Morishita, Kunihiko Takeyama, Toshio Shimizu, Noboru Yamamoto

Blood (2022) 140 (Supplement 1): 6211–6212.

https://doi.org/10.1182/blood-2022-157241

Published: 2022

Journal Articles

Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, Tohru Fujiwara, Hiroki Shima, Hironari Nishizawa, Chie Suzuki, Noriyuki Takahashi, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Blood (2022) 140 (Supplement 1): 2467–2468.

https://doi.org/10.1182/blood-2022-163073

Published: 2022

Journal Articles

Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2021-147645

Published: 2021

Journal Articles

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Blood (2019) 134 (Supplement_1): 743.

https://doi.org/10.1182/blood-2019-123382

Published: 2019

Journal Articles

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Tohru Fujiwara, MD PhD, Chie Suzuki, Tetsuro Ochi, Koya Ono, MD, Kei Saito, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Shinichi Fujimaki, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 2232.

https://doi.org/10.1182/blood-2019-123918

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Chie Suzuki, Tohru Fujiwara, MD PhD, Hiroki Shima, Koya Ono, MD, Kei Saito, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Shinichi Fujimaki, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 3523.

https://doi.org/10.1182/blood-2019-122618

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

NLRP6 regulates ZAP-70-erk signaling in both murine and human T cells and influences acute graft-versus-host disease(GVHD)

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Hematopoietic Stem/Progenitor Cell Intrinsic SAM Synthesis Is Required to Prevent p53 Pathway Activation By Maintaining DNA Stability

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Roles for Heme Synthesis in the Maintenance of Hematopoietic Stem and Progenitor Cells

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Transcription Factor GATA2 Is Inevitable for the Survival and Proper Differentiation of Thymic Multipotent Progenitor Cells By Gene Expression Orchestration

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only